Managing Director & Partner
Friedemann Wolf is a core member of the Health Care practice at Boston Consulting Group. He works on a broad range of topics with his clients in the fields of biopharma, consumer health, and animal health. Friedemann leads the firm’s work in customer engagement models for biopharma clients globally, as well as the consumer health and animal health businesses. He is particularly experienced in strategy and large-scale transformations, digital transformations, and marketing and sales related topics, with a focus on using data and analytics to drive go-to-market strategies. He also works with his clients on biotech venturing, digital health, and new technology strategies.
In his recent engagements, Friedemann led the go-to-market strategy transformation and next generation customer engagement model for one of his global pharma clients, and supported the development of digital health solutions for a specialty pharma business. He also supported the portfolio strategy and organizational transformation for a leading consumer health company, with a focus on accelerating the digital transformation. In addition, he worked with several biopharma companies on market launch and competitive strategies, as well as venturing and incubating new businesses.
Powerful new models are in the works, but effective implementation depends on building the right capabilities and enablers.
BCG’s latest survey on the impact of COVID-19 shows which changes in how doctors engage with the pharma industry will last beyond the pandemic.
The pandemic has transformed health care. Physicians expect long-term changes in how they interact with biopharma companies.